Ratings Reflect Region As Mixed Opportunity For Investors

BMI View: BMI's Pharmaceuticals and Healthcare Business Environment Ratings (BERs), which assess markets according to their risk/reward profile, show that the Americas have improved slightly from 49.0 out of 100 in Q411 to 50.4 in Q112, up by 0.3%. Looking back to Q111's score of 46.4, we note the region as a whole has undergone significant improvements over the last 12 months. While macroeconomic headwinds continue to lead to downward revisions to BMI's global economic growth forecasts, our healthcare and pharmaceutical projections for key markets across South America remain positive due to the region's strong industry rewards.

To read the full article, please choose one of the following options: